Many factors affect the cost of targeted therapy for adenocarcinoma, with annual costs ranging from thousands to tens of thousands of dollars for patients. Since the patients’ physical condition, previous treatment programs will be different, and the targeted drugs used are also different, the specific cost will be very different. Taking lung adenocarcinoma as an example, the annual cost of using domestically produced gefitinib is around 10,000 to 3,000 yuan, and in some areas it is within the scope of reimbursement of medical insurance, so the patient’s out-of-pocket expenses may be reduced. In addition, the price difference between domestic targeted drugs and imported targeted drugs is also relatively large, and the health insurance policy of each place is not the same, which will lead to different costs borne by the patients, and the specific costs can be consulted with the relevant doctors.